Quotient (NASDAQ:QTNT) will post its quarterly earnings results before the market opens on Tuesday, May 28th. Analysts expect Quotient to post earnings of ($0.44) per share for the quarter.
Shares of NASDAQ:QTNT opened at $9.40 on Monday. The stock has a market cap of $611.29 million, a P/E ratio of -4.65 and a beta of 1.25. Quotient has a 12 month low of $5.52 and a 12 month high of $11.15. The company has a debt-to-equity ratio of 4.95, a quick ratio of 6.05 and a current ratio of 6.87.
Several equities analysts recently commented on the stock. BidaskClub upgraded shares of Quotient from a “sell” rating to a “hold” rating in a report on Thursday. Zacks Investment Research upgraded shares of Quotient from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. ValuEngine downgraded shares of Quotient from a “strong-buy” rating to a “buy” rating in a report on Friday, April 19th. Finally, Jefferies Financial Group upped their price target on shares of Quotient from $11.00 to $13.50 and gave the company a “buy” rating in a report on Tuesday, March 5th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $11.75.
ILLEGAL ACTIVITY NOTICE: “Quotient (QTNT) Scheduled to Post Quarterly Earnings on Tuesday” was published by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4353594/quotient-qtnt-scheduled-to-post-quarterly-earnings-on-tuesday.html.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
See Also: What is a dead cat bounce?
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.